1. Home
  2. RYM vs LITS Comparison

RYM vs LITS Comparison

Compare RYM & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RYM

RYTHM Inc.

N/A

Current Price

$26.56

Market Cap

37.6M

ML Signal

N/A

LITS

Lite Strategy Inc.

N/A

Current Price

$1.17

Market Cap

41.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RYM
LITS
Founded
2016
2000
Country
United States
United States
Employees
141
4
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.6M
41.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RYM
LITS
Price
$26.56
$1.17
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
15.4K
232.5K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.00
$0.95
52 Week High
$53.65
$3.03

Technical Indicators

Market Signals
Indicator
RYM
LITS
Relative Strength Index (RSI) 62.11 54.03
Support Level $15.26 $1.17
Resistance Level $30.90 $1.26
Average True Range (ATR) 2.42 0.06
MACD 0.16 0.01
Stochastic Oscillator 67.57 83.33

Price Performance

Historical Comparison
RYM
LITS

About RYM RYTHM Inc.

Rythm Inc is a USA Based company. The company's portfolio of brands delivers well-being to millions of Americans every year. The company features some of the recognized and trusted names in the cannabis and hemp industries, including RYTHM, incredibles, Dogwalkers, Beboe, Senorita THC Margaritas, &Shine, Doctor Solomon's and Good Green in thousands of physical locations and online channels. With products rooted in quality, safety, and innovation, the Company is shaping cannabis experiences that enhance daily life.

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Share on Social Networks: